All In Biotech

Drug Trial Radar · NCT05271409

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab as Monotherapy or in Addition to Baseline Therapy in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 139 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

139

Actual

Start

Aug 30, 2022

Primary completion

Nov 20, 2025

Study completion May 20, 2028

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Chugai Pharmaceutical
First posted
Mar 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment period. Participants who experience an adjudicated relapse or complete the DB period can enter open-label extension (OLE) period. After the primary clinical cutoff date (CCOD), additional adolescent participants may be enrolled directly into the OLE period.

Conditions

  • Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Interventions

  • SatralizumabDrug

    Study drug will be administered by subcutaneous (SC) injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.

  • PlaceboOther

    Placebo will be administered by SC injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time From Randomization to the First Occurrence of a MOGAD Relapse in the DB Treatment Period, as Determined by an Adjudication Committee (CEC)Time frame: Up to approximately 44 months

Locations

53 sites in 11 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of California Irvine - Manchester Pavilion

    Irvine, California

  • University of Colorado - Anschutz Medical Campus (University of Colorado Health Sciences Center)

    Aurora, Colorado

  • Medstar Georgetown University Hospital

    Washington D.C., District of Columbia

  • University of Florida College of Medicine Gainesville

    Gainesville, Florida

  • Johns Hopkins

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis

    Owosso, Michigan

  • Mayo Clinic - Rochester

    Rochester, Minnesota

  • Washington University School of Medicine in St. Louis

    St Louis, Missouri

  • NYU Langone

    New York, New York

  • University of Cincinnati

    Cincinnati, Ohio

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Premier Neurology

    Greenville, South Carolina

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Brain and Mind Research Institute

    Camperdown, New South Wales, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • Perron Institute for Neurological and Translational Science

    Nedlands, Western Australia, Australia

  • Hospital Universitario Gaffree e Guinle

    Rio de Janeiro, Brazil

  • Instituto de Neurologia de Curitiba

    Curitiba, Paraná, Brazil

  • Instituto do Cerebro do Rio Grande do Sul

    Porto Alegre, Rio Grande do Sul, Brazil

  • Centro de Pesquisas Clinicas

    São Paulo, São Paulo, Brazil

  • Children's Hospital of Eastern Ontario

    Ottawa, Ontario, Canada

  • MUCH - Montreal Neurological Institute & Hospital

    Montreal, Quebec, Canada

  • Hopital Pierre Wertheimer

    Bron, France

  • CH de Bicêtre

    Le Kremlin-Bicêtre, France

  • ECRC Experimental and Clinical Research Center, Charité Campus Berlin Buch, Memory Clinic

    Berlin, Germany

  • St. Josef-Hospital, Klinik für Neurologie

    Bochum, Germany

  • Vestische Kinder- und Jugendklinik Datteln

    Datteln, Germany

  • Universitätsklinikum Düsseldorf

    Düsseldorf, Germany

  • Universitätsklinikum Mannheim

    Mannheim, Germany

  • Klinikum Großhadern, LMU

    Munich, Germany

  • Hadassah University Hospital Ein Kerem

    Jerusalem, Israel

  • Fondazione Istituto Neurologico Mondino IRCCS

    Pavia, Lombardy, Italy

  • Azienda Sanitaria Ospedaliera S. Luigi Gonzaga

    Orbassano, Piedmont, Italy

  • Azienda Ospedaliera Universitaria Integrata Verona

    Verona, Veneto, Italy

  • Chiba University Hospital

    Chiba, Japan

  • Kyushu University Hospital

    Fukuoka, Japan

  • Southern Tohoku Medical Clinic

    Fukushima, Japan

  • Kobe University Hospital

    Hyōgo, Japan

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.